Season 2 (2021-2030)

Immunology - Small Molecules (23)

Modality Indication Targets Stage Company Project No. Detail
1 Developing the drug candidates for psoriasis treatment using small molecule with IRAK.1/4 inhibition
Small Molecules Psoriasis IRAK1/4 Candidate Dongwha Pharm Co.,Ltd. RS-2023-00284094
2 Development of a novel RIPK1 inhibitor for autoimmune disease(BSC.1300)
Small Molecules Autoimmune diseases RIPK1 Candidate BiSiChem RS-2023-00259271
3 Development of a novel topical treatment for atopic dermatitis by modulating TSLP signaling
Small Molecules Atopic dermatitis TSLP/TSLPR Preclinical AmtixBio RS-2023-00258738
4 Development of a therapeutic agent for ulcerative colitis based on the regeneration mechanism of intestinal mucosa using an AIbased drug development platform
Small Molecules Ulcerative colitis 15.PGDH Candidate Innovo Therapeutics, Inc. RS-2023-00258490
5 Discovery of Selective IRAK4 Degrader based on Protac Technology
Small Molecules Systemic Lupus Erythematosus IRAK4 Lead College of Pharmacy, Gachon University RS-2023-00218618
6 Completion of non-clinical studies and IND authorization for a 3rd generation multiple sclerosis drug candidate based on biased modulation that overcomes the limitations of cardiac side effects
Small Molecules Multiple Sclerosis S1P1 Preclinical CUREVERSE RS-2023-00217346
7 Development of Hit/Lead compound using PKCη inhibitory drugs for treating multiple sclerosis
Small Molecules Multiple Sclerosis PKCη Hit Hanyang University RS-2023-00217324
8 Development of functional hyaluronic acid nanoparticle lead compounds for treatment of skin inflammation
Small Molecules Psoriasis Cannabinoid 1 receptor Hit Ajou University RS-2023-00217308
9 Development of STAT6 blocking therapeutic drug in systemic sclerosis with targeting profibrotic T cells and fibroblasts
Small Molecules Systemic Sclerosis STAT6 Hit The catholic university, medical college, LaTIM (Lab of Translational ImmunoMedicine) RS-2023-00217274
10 Identification a lead small-molecule drug to treat osteoarthritis through a cartilage regeneration mechanism
Small Molecules Osteoarthritis OSCAR Hit KaiPharm Co., Ltd. RS-2022-00167006
11 Development of a therapeutic agent for ulcerative colitis by regulating glycogen metabolism of
 immune cells and intestinal epithelial cells
Small Molecules Ulcerative Colitis PYGL Phase 1 INNOVO Therapeutics RS-2022-00166802
12 Clinical development of a novel synthetic AHR agonist PB542 as an IBD therapeutics
Small Molecules Crohn's disease AhR Preclinical Parenchyma Biotech RS-2022-00165759
13 Discovery of Leads as LRRK2 inhibitors for the treat of Crohn’s disease
Small Molecules Crohn's disease LRRK2 Lead Chung Ang University HN22C0690
14 Discovery of Lead for a First-in-Class Drug Treating Inflammatory Bowel Disease (IBD)
Small Molecules Ulcerative colitis, Crohn's disease PIN1 Lead PimedBio HN22C0056
15 Discovery of non-clinical candidates of new PKM2 activator that cure inflammation and fibrosis at the same time through cell metabolism modulation
Small Molecules Rheumatoid arthritis, IBD PKM2 Candidate Lmito Therapeutics HN21C0943
16 Development of a therapeutic agent for ulcerative colitis by regulating glycogen metabolism of immune cells and intestinal epithelial cells
Small Molecules Ulcerative colitis PYGL Preclinical INNOVO Therapeutics HN21C0604
17 The generation of candidate for atopic dermatitis via selective STAT3 inhibition
Small Molecules Atopic dermatitis STAT3 Candidate C&C Research Laboratories HN21C0543
18 Development of anti-fibrosis therapeutics for systemic sclerosis using SOS1- RAS interaction-specific blockade
Small Molecules Systemic Sclerosis SOS1/RAS Hit Kyungpook National University HN21C0307
19 Discovery study of CR-E1 targeting psoriasis lead compounds by regulating Th17 mechanism
Small Molecules Psoriasis CR-E1 Hit Curogen Technology HN21C0250
20 Discovery of lead small molecules to control NLRP3 inflammasome
Small Molecules Psoriasis, Inflammatory disease NLRP3 Lead Ajou University HN21C1058
21 Development of SCED-based lead compounds for atopic dermatitis
Small Molecules Atopic dermatitis EGR1 Hit Konkuk University HN21C0984
22 Development of TYK2 pseudokinase domain selective inhibitor for autoimmune treatment
Small Molecules Psoriasis, Rheumatoid Arthritis Tyk2 Lead CrystalGenomic Inc. HN21C0189
23 Development of small-molecule asthma drug that inhibits the binding of IL-33 to its receptor
Small Molecules Asthma IL-33 Lead AZCURIS HN21C0187
BACK